BD Expects Alaris Infusion Pump To Return To US Market Next Year
Executive Summary
The company stopped shipping Alaris in early 2020 after the FDA requested a new 510(k) for modifications and the device has been the subject of several recalls since then.
You may also be interested in...
Meet Embecta! Becton Dickinson Completes Diabetes Spin-Off
Becton Dickinson has formally completed the planned spin-off of its diabetes business within the timeframe it projected about a year ago. The new company, called embecta, is one of the largest producers of diabetes injection devices.
Slow Q1 For Baxter, But Board Remains Confident Of Turnaround
Baxter International recorded slight revenue increases during quarter one of 2021, with sales still impacted by COVID-19. Its board remains optimistic , pointing towards new product releases and “operational strength” as redeeming factors.
Class I Recall: More Alaris Infusion Pumps Yanked From Market
The US FDA has labeled the recall of nearly 2,500 Alaris Model 8100 infusion pumps as high-risk class I.